Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?

Novo Nordisk (NVO) recently lowered its 2025 sales and operating profit guidance, attributing the revision to weaker U.S. demand for its key GLP-1 drugs, Wegovy and Ozempic, amid persistent competition from illegal compounded alternatives and Eli Lilly's market-share gains with Zepbound and Mounjaro. These pressures, compounded by disappointing late-stage trial results for its next-generation obesity drug CagriSema and an ongoing leadership transition, have contributed to NVO's 44% year-to-date stock underperformance and signal a challenging near-term outlook for the company's core growth drivers.

Analysis

Novo Nordisk is facing significant near-term headwinds, underscored by a sharp downward revision of its 2025 guidance. The company slashed its sales growth forecast to 8-14% from 13-21% and its operating profit growth estimate to 10-16% from 16-24%. This revision is driven by slowing momentum for its key GLP-1 drugs, Wegovy and Ozempic, particularly in the critical U.S. market. The pressure is multi-faceted, stemming from intense competition from Eli Lilly's Zepbound, which demonstrated superior efficacy in a head-to-head trial (20.2% vs. 13.7% weight loss), and the persistent market erosion from illegal compounded semaglutide alternatives. These challenges are compounded by internal issues, including disappointing late-stage trial data for its next-generation obesity drug, CagriSema, and a leadership transition with the CEO stepping down. The market has reacted severely, with NVO's stock declining 44% year-to-date, drastically underperforming its industry's 5% decline. While the stock now trades at a forward P/E of 11.87, a deep discount to its five-year mean of 29.25, this reflects profound investor concern over pipeline setbacks, regulatory hurdles like Medicare's non-coverage of weight-loss drugs, and a deteriorating competitive position.

Key Decisions for Investors

• Given the slashed guidance, significant stock underperformance, and intensifying competitive pressure from clinically superior rival products, investors should consider reducing exposure to NVO as the near-term risk/reward profile appears skewed to the downside.
• Closely monitor the market share dynamics between NVO's Wegovy/Ozempic and Eli Lilly's Zepbound/Mounjaro, as continued gains by LLY represent a direct and material threat to NVO's core revenue streams.
• The current discounted valuation may be a value trap; look for clear catalysts, such as a successful strategy to combat compounded drugs, positive pipeline developments beyond CagriSema, or a stabilization in market share, before considering a long position.
• Pay attention to the upcoming Q2 earnings report on August 6 for any further details on the slowdown in U.S. uptake and management's strategy under new leadership to address the competitive and regulatory challenges.